title: Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.
abstract: We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.
authors.affiliation: Cancer Research UK Centre in Leeds, Cookridge Hospital, Leeds LS16 6QB, UK.
authors.forename: M S
authors.initials: MS
authors.lastname: Braun
authors.forename: F
authors.initials: F
authors.lastname: Adab
authors.forename: C
authors.initials: C
authors.lastname: Bradley
authors.forename: K
authors.initials: K
authors.lastname: McAdam
authors.forename: G
authors.initials: G
authors.lastname: Thomas
authors.forename: N J
authors.initials: NJ
authors.lastname: Wadd
authors.forename: D
authors.initials: D
authors.lastname: Rea
authors.forename: R
authors.initials: R
authors.lastname: Philips
authors.forename: C
authors.initials: C
authors.lastname: Twelves
authors.forename: J
authors.initials: J
authors.lastname: Bozzino
authors.forename: C
authors.initials: C
authors.lastname: MacMillan
authors.forename: M P
authors.initials: MP
authors.lastname: Saunders
authors.forename: R
authors.initials: R
authors.lastname: Counsell
authors.forename: H
authors.initials: H
authors.lastname: Anderson
authors.forename: A
authors.initials: A
authors.lastname: McDonald
authors.forename: J
authors.initials: J
authors.lastname: Stewart
authors.forename: A
authors.initials: A
authors.lastname: Robinson
authors.forename: S
authors.initials: S
authors.lastname: Davies
authors.forename: F J
authors.initials: FJ
authors.lastname: Richards
authors.forename: M T
authors.initials: MT
authors.lastname: Seymour
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011446:Prospective Studies; D015996:Survival Rate; D013997:Time Factors
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil